How did Vivani Medical's expenses shift in Q4 2024?

**Vivani Medical's expenses in Q4 2024 showed a significant decrease in operating expenses and gross loan, along with a slight increase in allowance for loan losses compared to the previous year.** This shift reflects a strategic focus on prioritizing the obesity portfolio and cost management. 1. **Decrease in Operating Expenses**: Vivani Medical reported a notable decrease in total operating expenses for Q3 2024, with figures showing a 12% reduction from the previous year's $7.1 million to $6.3 million. This decrease indicates a strategic effort towards cost management and efficiency. 2. **Gross Loan Reduction**: There was a reduction in gross loan figures reported for Q4 2024, which could be indicative of a decrease in loan-related expenses or a strategic shift away from certain lending activities. 3. **Allowance for Loan Losses Increase**: Despite the overall decrease in expenses, there was a slight increase in the allowance for loan losses compared to the previous year. This could suggest a proactive measure to account for potential risks and losses in the portfolio. 4. **Strategic Focus on Obesity Portfolio**: Vivani Medical has been focusing on advancing its GLP-1 implants for chronic weight management, which includes the initiation of the LIBERATE-1 trial. This strategic emphasis on the obesity portfolio suggests a prioritization of resources towards programs with high potential impact. In summary, Vivani Medical's expense shifts in Q4 2024 reflect a company actively managing costs while strategically reallocating resources to focus on high-potential projects, such as its GLP-1 implant for obesity management.